Yu Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu Tian has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Bin Zhang
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 shared publications - Chao Wan
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
5 shared publications - Fang Huang
Huazhong University of Science and Technology 1 Cancer Center, Union Hospital, Tongji Medical College Wuhan, China
5 shared publications - Haibo Zhang
Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, China
5 shared publications - Jie Li
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 shared publications - Jingshu Meng
Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China
5 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1-S5 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Table S1 presents the sequences of primers used for RT-qPCR analysis. Table S2 lists the sequences of primers used for ChIP-PCR. Table S3 contains the differentially expressed metabolites identified in tumor tissues of Lewis tumor-bearing mice treated with IgG2 (Ctrl) or anti-PD-1 monoclonal antibody. Table S4 summarizes the differentially expressed genes in untreated and IFN-γ-treated bone marrow-derived macrophages (BMDMs). Table S5 provides the differentially expressed genes in bone marrow-derived dendritic cells (BMDCs) under IFN-γ versus IFN-γ + 4-OI treatment conditions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1-S5 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Table S1 presents the sequences of primers used for RT-qPCR analysis. Table S2 lists the sequences of primers used for ChIP-PCR. Table S3 contains the differentially expressed metabolites identified in tumor tissues of Lewis tumor-bearing mice treated with IgG2 (Ctrl) or anti-PD-1 monoclonal antibody. Table S4 summarizes the differentially expressed genes in untreated and IFN-γ-treated bone marrow-derived macrophages (BMDMs). Table S5 provides the differentially expressed genes in bone marrow-derived dendritic cells (BMDCs) under IFN-γ versus IFN-γ + 4-OI treatment conditions.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1-S10 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Figure S1 shows the metabolic alterations induced by anti-PD-1 treatment in mice. Figure S2 presents the effects of itaconate on anti-PD-1 therapy in vivo. Figure S3 shows the impact of Acod1 deletion on the tumor immune microenvironment. Figure S4 presents the oxidative stress levels in DCs and TAMs within the tumor immune microenvironment. Figure S5 shows the efficiency of immune cell depletion in vivo. Figure S6 demonstrates that the impact of Acod1 deletion on anti-PD-1 therapy is dependent on CD8+ T cells. Figure S7 presents ACOD1 expression patterns in the tumor immune microenvironment. t-SNE projections and violin plots illustrate ACOD1 expression across myeloid and immune cell clusters in lung adenocarcinoma samples. Figure S8 shows the transcriptional regulation of Acod1 via the IFN-γ-JAK/STAT1 axis. Figure S9 presents the inhibitory effects of itaconate on DC antigen cross-presentation. Figure S10 shows the effects of itaconate on DC metabolism and signaling pathways.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-S10 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Figure S1 shows the metabolic alterations induced by anti-PD-1 treatment in mice. Figure S2 presents the effects of itaconate on anti-PD-1 therapy in vivo. Figure S3 shows the impact of Acod1 deletion on the tumor immune microenvironment. Figure S4 presents the oxidative stress levels in DCs and TAMs within the tumor immune microenvironment. Figure S5 shows the efficiency of immune cell depletion in vivo. Figure S6 demonstrates that the impact of Acod1 deletion on anti-PD-1 therapy is dependent on CD8+ T cells. Figure S7 presents ACOD1 expression patterns in the tumor immune microenvironment. t-SNE projections and violin plots illustrate ACOD1 expression across myeloid and immune cell clusters in lung adenocarcinoma samples. Figure S8 shows the transcriptional regulation of Acod1 via the IFN-γ-JAK/STAT1 axis. Figure S9 presents the inhibitory effects of itaconate on DC antigen cross-presentation. Figure S10 shows the effects of itaconate on DC metabolism and signaling pathways.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Table S1-S5 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Table S1 presents the sequences of primers used for RT-qPCR analysis. Table S2 lists the sequences of primers used for ChIP-PCR. Table S3 contains the differentially expressed metabolites identified in tumor tissues of Lewis tumor-bearing mice treated with IgG2 (Ctrl) or anti-PD-1 monoclonal antibody. Table S4 summarizes the differentially expressed genes in untreated and IFN-γ-treated bone marrow-derived macrophages (BMDMs). Table S5 provides the differentially expressed genes in bone marrow-derived dendritic cells (BMDCs) under IFN-γ versus IFN-γ + 4-OI treatment conditions.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1-S5 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Table S1 presents the sequences of primers used for RT-qPCR analysis. Table S2 lists the sequences of primers used for ChIP-PCR. Table S3 contains the differentially expressed metabolites identified in tumor tissues of Lewis tumor-bearing mice treated with IgG2 (Ctrl) or anti-PD-1 monoclonal antibody. Table S4 summarizes the differentially expressed genes in untreated and IFN-γ-treated bone marrow-derived macrophages (BMDMs). Table S5 provides the differentially expressed genes in bone marrow-derived dendritic cells (BMDCs) under IFN-γ versus IFN-γ + 4-OI treatment conditions.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Figure S1-S10 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Figure S1 shows the metabolic alterations induced by anti-PD-1 treatment in mice. Figure S2 presents the effects of itaconate on anti-PD-1 therapy in vivo. Figure S3 shows the impact of Acod1 deletion on the tumor immune microenvironment. Figure S4 presents the oxidative stress levels in DCs and TAMs within the tumor immune microenvironment. Figure S5 shows the efficiency of immune cell depletion in vivo. Figure S6 demonstrates that the impact of Acod1 deletion on anti-PD-1 therapy is dependent on CD8+ T cells. Figure S7 presents ACOD1 expression patterns in the tumor immune microenvironment. t-SNE projections and violin plots illustrate ACOD1 expression across myeloid and immune cell clusters in lung adenocarcinoma samples. Figure S8 shows the transcriptional regulation of Acod1 via the IFN-γ-JAK/STAT1 axis. Figure S9 presents the inhibitory effects of itaconate on DC antigen cross-presentation. Figure S10 shows the effects of itaconate on DC metabolism and signaling pathways.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-S10 from Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Figure S1 shows the metabolic alterations induced by anti-PD-1 treatment in mice. Figure S2 presents the effects of itaconate on anti-PD-1 therapy in vivo. Figure S3 shows the impact of Acod1 deletion on the tumor immune microenvironment. Figure S4 presents the oxidative stress levels in DCs and TAMs within the tumor immune microenvironment. Figure S5 shows the efficiency of immune cell depletion in vivo. Figure S6 demonstrates that the impact of Acod1 deletion on anti-PD-1 therapy is dependent on CD8+ T cells. Figure S7 presents ACOD1 expression patterns in the tumor immune microenvironment. t-SNE projections and violin plots illustrate ACOD1 expression across myeloid and immune cell clusters in lung adenocarcinoma samples. Figure S8 shows the transcriptional regulation of Acod1 via the IFN-γ-JAK/STAT1 axis. Figure S9 presents the inhibitory effects of itaconate on DC antigen cross-presentation. Figure S10 shows the effects of itaconate on DC metabolism and signaling pathways.
- 4 March 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (10) , 1842-1856
Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Adaptive resistance to immunotherapy remains a significant challenge in cancer treatment. The reshaping of the tumor immune microenvironment in response to therapeutic pressures is a crucial factor contributing to this resistance. In this study, by comprehensive metabolic profiling of tumor tissues, we identified elevated itaconate in response to anti–PD-1 therapy as an adaptive resistance mechanism that promoted immune escape and tumor progression. CD8+ T-cell–derived IFNγ induced a significant upregulation of cis-aconitate decarboxylase 1 (ACOD1) in macrophages via the JAK–STAT1 pathway, thereby rewiring the Krebs cycle toward itaconate production. In murine models, macrophage-specific deletion of Acod1 increased the antitumor efficacy of anti–PD-1 therapy and improved survival. Additionally, itaconate and its derivative, 4-octyl itaconate, suppressed the tumor antigen presentation and cross-priming ability of dendritic cells, resulting in the impairment of antigen-specific T-cell antitumor responses. In summary, these findings identify an IFNγ-dependent immunometabolic mechanism of anti–PD-1 resistance, providing a promising strategy for combination therapy. Significance: Elevated itaconate production by macrophages induced by IFNγ is a critical negative feedback immunoregulatory metabolic response to anti-PD-1 immunotherapy that inhibits the cross-priming function of dendritic cells and confers immunotherapy resistance.
- 4 March 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (10) , 1842-1856
Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti–PD-1 Immunotherapy
Adaptive resistance to immunotherapy remains a significant challenge in cancer treatment. The reshaping of the tumor immune microenvironment in response to therapeutic pressures is a crucial factor contributing to this resistance. In this study, by comprehensive metabolic profiling of tumor tissues, we identified elevated itaconate in response to anti–PD-1 therapy as an adaptive resistance mechanism that promoted immune escape and tumor progression. CD8+ T-cell–derived IFNγ induced a significant upregulation of cis-aconitate decarboxylase 1 (ACOD1) in macrophages via the JAK–STAT1 pathway, thereby rewiring the Krebs cycle toward itaconate production. In murine models, macrophage-specific deletion of Acod1 increased the antitumor efficacy of anti–PD-1 therapy and improved survival. Additionally, itaconate and its derivative, 4-octyl itaconate, suppressed the tumor antigen presentation and cross-priming ability of dendritic cells, resulting in the impairment of antigen-specific T-cell antitumor responses. In summary, these findings identify an IFNγ-dependent immunometabolic mechanism of anti–PD-1 resistance, providing a promising strategy for combination therapy. Significance: Elevated itaconate production by macrophages induced by IFNγ is a critical negative feedback immunoregulatory metabolic response to anti-PD-1 immunotherapy that inhibits the cross-priming function of dendritic cells and confers immunotherapy resistance.